INFORMATION DISCLOSURE STATEMENT BY APPLICANT	ATTY. DOCKET NO. 12961/46102	APPLICATION NO. 10/766,263	
Form PTO-140 PE	APPLICANT Claus MEESE et al.		
AUG 2 3 2005	FILING DATE January 27, 2004	GROUP 1624	
VEA S			

TRADEMETU. S. PATENT DOCUMENTS*

EXAMINER INITIAL	PATENT/PUBLICATION NUMBER	PATENT/PUBLICATION DATE	NAME	CLASS	SUBCLASS	FILING DATE	
24	2,556,636	June 12, 1951	Nathan Sperber et al.	240	247.1		
31	2,567,245	September 11, 1951	Nathan Sperber et al.	260	296		
27	2,676,964	April 27, 1954	Nathan Sperber et al.	200	256,4		
2+	. 3,261,841	July 19, 1966	Bernard L. Zenitz	260	292		

^{*-} copies of U.S. references are not enclosed

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
-						YES	МО
21	830,193	February 04, 1952	DE			х	
27	685 696	January 07, 1953	GB	-			
2	689 835	April 08, 1953	GB	_			
21	690 274	April 15, 1953	GB	-			
2+	692 931	June 17, 1953	GB				
7	1 169 944	November 05, 1969	GB				
21	1 169 945	November 05, 1969	GB				
25	WO 03/021271	March 13, 2003	PCT				

OTHER DOCUMENTS

EXAMINER INITIAL	AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
Zr	Abstracts from the 26 th Annual Meeting of the International Incontinence Society, August 27-30, 1996, Gillberg et al., abstract 33, Neurology and Urodynamics 15:308-309
27	Andersson & Hedlund, "Pharmacological perspective on the physiology of the lower urinay tract," 2002, Urology 60(Suppl. 5A):13-20
21	Committee for Proprietary Medicinal Products, "The assessment of the potential for QT interval prolongation by non-cardiovascular medicinal products," CPMP/986/96, December 17, 1997
21	Gardner & Altman, "Confidence intervals rather than P values: estimation rather than hypothesis testing," 1986, Br. Med. J. 292:746-750
21	Kang et al., "Cardiac ion channel effects of Tolterodine," 2004, J. Pharmacol. Exper. Thera. 308:935-940
34	Klosa, "Eine Neue Synthesemethode der Darstellung von Diarylalkylaminen," 1966, Journal für Praktische Chemie 4:312-334 (in German) with English translation

EXAMENTER	Allh-	PATE 2	SEPTEMBER 2005

EXAMINER INITIAL	AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.			
21	Lipinsky et al., "Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings," 1997, Adv. Drug Deliv. Rev. 23:3-25			
7	Netzer et al., "Screening lead compounds for QT interval prolongation," 2001, Drug Discovery Today 6:78-84			
孟	Nilvebrant et al., "Differences between binding affinities of some antimuscarinic drugs in the parotid gland an those in the urinary bladder and ileum," 1983, Acta Pharmacol. et Toxicol. 53:304-313			
ZT	Pharmacology/Toxicology Review from Application Number 21-518, Center for Drug Evaluation and Research, pages 1-3 (2004)			
25	Roy et al., "HERG, a primary human ventricular target of the nonsedating antihistamine terfenadine," 1996, 94:817-823			

			\ 		
EXAMINER	Ac	又	~	~	DATE CONSIDERED 2 SEPTEMBER 2005
EXAMINER: Initial if	citation consider	ed.	wheth	er or not citation is in conformance with M.P.E.P. 609: draw	

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.